Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Relugolix Combination Drug Approved in EU for Uterine Fibroids
July 21, 2021
- Kyowa Suspending Alfacalcidol Supply; Chugai Curbs Further Products
July 21, 2021
- Sanofi to Transfer Plaquenil’s Japan Marketing Rights to Asahi Kasei on Oct. 1
July 20, 2021
- Ono Initiates PII Trial of BTK Inhibitor Velexbru for PCNSL in US
July 20, 2021
- Shionogi Bags Rights to COVID-19 Nasal Vaccines
July 20, 2021
- Kyosomirai Controls Shipments for Generic Calcitriol Amid Vitamin D3 Preparation Shortage
July 20, 2021
- Shipment Adjustments/Pauses for Choseido-Made Products Grow to 42
July 20, 2021
- Sawai’s Shipment Restrictions Now Reaches 385 Products
July 20, 2021
- Towa to Launch Cymbalta Generics on Aug. 30, Nipro on July 21/27
July 19, 2021
- Shionogi’s Peptide Vaccine Fails in PIII for Esophageal Cancer
July 19, 2021
- Guilty Rulings for 3 Wholesalers, Employees Now Final and Binding: Bid-Rigging Trial
July 19, 2021
- Arcalis Sees Opportunities in mRNA Drugs, Eyes Tens of Billions of Yen in CDMO Sales
July 19, 2021
- GHIT Fund to Bankroll 97 Million Yen in TB Drug Discovery Project
July 16, 2021
- Nichi-Iko to Cease Marketing of 9 Products Including Teva Takeda Drugs
July 15, 2021
- Nippon Shinyaku Sues Sarepta over DMD Therapy Patents in US
July 15, 2021
- Guilty Ruling for Ono Employees Now Final and Binding: Onoact Case
July 15, 2021
- Takeda Expecting Delay in Entyvio Biosimilar Entry in Europe: CFO
July 14, 2021
- Shionogi to Support Access to Cefiderocol in Low/Middle-Income Nations
July 14, 2021
- Eisai Taps Continuous Manufacturing for Tazverik, Eyes Its Use for Other Oncology Assets Too
July 14, 2021
- Astellas/Affinivax Pneumococcal Vaccine Delivers in PII, Gets Breakthrough Therapy Tag
July 14, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…